semaglutide and cardiovascular outcomes in obesity without diabetes journal club Diabetes: The SELECT Trial Semaglutide and cardiovascular outcomes by

Obermeier B, Daneman R, Ransohoff RM

The National Institutes of Health (NIH) warns that chronic alcohol users are particularly vulnerable to acetaminophen-induced liver injury, making it essential to avoid alcohol while taking the medication

To see real benefits, it is often more effective to eat sulfur-rich foods that help your body produce its own glutathione or use a liposomal supplement designed for better absorption

Instead of short bursts of appetite regulation, your body receives steady support throughout the day and week

Some individuals experience injection site reactions or sensitivity to components of the injection

Translational perspective for the use of dual GLP-1R/GcgR agonists for obesity Multiple clinical trials involving GLP-1R/GcgR co-agonists are currently underway (Table 1)